Review

A Paradigm Shift in the Outpatient Approach to Liver Function Tests

Authors: Viplove Senadhi, DO

Abstract

The American Gastroenterological Association (2002), Canadian Medical Association (2005), and the Centers for Disease Control and Prevention (2006) released guidelines to screen patients with mild elevations of liver enzymes for hepatitis B and hepatitis C. Mildly elevated liver enzymes were defined as less than five times the upper limit of normal, but above the normal reference range. The rationale for this recommendation was based on many factors including cost effectiveness, lab variation, and ultimately, for better patient care.


Chronic hepatitis B and C have values of transaminases that fluctuate between normal and mildly abnormal. Screening patients with even mild elevations of transaminases allows many chronic hepatitis patients to be diagnosed early in the course of their disease. Diagnosing these patients early in their disease course leads to better treatment response, decreased progression to cirrhosis, lower viral loads leading to decreased incidence of extrahepatic manifestations, prevention of hepatocellular carcinoma, and decreased likelihood of liver transplantation.


There are organizations which recommend discontinuing hepatotoxic medications such as acetaminophen or nonsteroidal anti-inflammatory drugs and reevaluating the patient in three months. However, this recommendation misses a number of hepatitis patients for the reasons aforementioned. The obesity epidemic has clouded the diagnosis of hepatitis B/C as patients that have obesity, diabetes mellitus, and metabolic syndrome are not being screened due the presumptive diagnosis of nonalcoholic fatty liver disease.


Not screening patients in the setting of obesity is not cost-effective and also leads to increased morbidity, as we will discuss in this manuscript. Additionally, it has been proven in the literature that it is more cost-effective to screen for hepatitis B/C in high-prevalence areas, than to reassess the patient months later, and potentially miss a diagnosis of hepatitis B/C. The overall goal of this study is to increase screening awareness of patients with mild transaminitis elevations through publication in order to diagnose patients with hepatitis B and C prior to the development of chronic liver disease.

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. Sox HC, Blatt MA, Higgins MC, et al. Medical Decision Making. Boston, MA, Butterworth-Heinemann, 1988.
 
2. Haber MM, West AB, Haber AD, et al. Relationship of aminotransferases to liver histological status in chronic hepatitis C. Am J Gastroenterol 1995;90:1250-1257.
 
3. Gholson CF, Morgan K, Catinis G, et al. Chronic hepatitis C with normal aminotransferase levels: a clinical histological study. Am J Gastroenterol 1997;92:1788-1792.
 
4. Mofrad P, Contos MJ, Haque M, et al. Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology 2003;37:1286-1292.
 
5. AGA technical review on the evaluation of liver chemistry tests. Gastroenterology 2002;123:1367-1384.
 
6. Heffler S, Levit K, Smith S, et al. Health spending growth up in 1999: faster growth expected in the future. Health Aff 2001;20:193-202.
 
7. Yim JY, Lok AS-F. Chronic hepatitis B: deciding when to treat. Hepatology 2006;43:S173-S181.
 
8. Bertolini AS, Fusco O, Berardi E, et al. Screening for chemotherapy-induced reactivation of hepatitis B virus infection: an institutional experience. J Clin Oncol 2008;26(suppl). Abstract 20563.
 
9. Alter HJ, Seeff LB. Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome. Semin Liver Dis 2000;20:17-35.
 
10. National Institutes of Health Consensus Development Conference Statement. Management of hepatitis C: 2002. Hepatology 2002;36:S3-S20.
 
11. Morrow PH, Hortobagyl GN, Rolston KH, et al. Effects of hepatitis C on the treatment of breast cancer. Ann Oncol 2010;21:1233-1236.
 
12. Misiani R, Bellavita P, Fenili D, et al. Interferon alfa-2a therapy in cryoglobulinemia associated with hepatitis C virus. N Eng J Med 1994; 330:751-756.
 
13. Vanni E, Abate M, Gentilcore E, et al. Sites and mechanisms of insulin resistance in nonobese, nondiabetic patients with chronic hepatitis C. Hepatology 2009;50:697-706.
 
14. Wang L-Y, You S-L, Lu S-N, et al. Risk of hepatocellular carcinoma and habits of drinking alcohol, bctcl quid chewing and cigarette smoking: a cohort of 2416 HBsAg-seropositive and 9421 HBsAg-seronegative male residents in Taiwan. Cancer Causes Control 2003;14:241-250.
 
15. Dienstag J, Isselbacher K. Acute viral hepatitis. In: Harrison's Principle of Internal Medicine. New York: McGraw-Hill Companies, 2005;1822-1838.
 
16. Green RM, Flamm S, American Gastroenterological Association. AGA technical review on the evaluation of liver function tests. Gastroenterology 2002;123:1367-1384.
 
17. Giannini EG, EG Testa R, Savarino V. Liver enzyme alteration: a guide for clinicians. Can Med Assoc J 2005;172:367-379.
18. Sroczynski G, Esteban E, Conrads-Frank A, et al. Long-term effectiveness and cost effectiveness of screening for hepatitis C virus infection. Eur J Public Health 2009;19:245-253.